BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 1281076)

  • 1. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
    Frampton J; Buckley MM; Fitton A
    Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and therapeutic effects of nicorandil.
    Kinoshita M; Sakai K
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1075-88. PubMed ID: 2150592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.
    Markham A; Plosker GL; Goa KL
    Drugs; 2000 Oct; 60(4):955-74. PubMed ID: 11085202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
    Krumenacker M; Roland E
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S93-102. PubMed ID: 1282184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
    Roland E
    Eur Heart J; 1993 Jul; 14 Suppl B():48-52. PubMed ID: 8370373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
    Döring G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease.
    Goldschmidt M; Landzberg BR; Frishman WH
    J Clin Pharmacol; 1996 Jul; 36(7):559-72. PubMed ID: 8844437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical use of potassium channel activators in angina pectoris: efficacy and tolerance].
    Specchia G; Marsico F; Micheletti T; Bona M
    Cardiologia; 1995 Dec; 40(12 Suppl 1):91-5. PubMed ID: 8998788
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate.
    Araki H; Hayata N; Matsuguchi T; Nakamura M
    Clin Ther; 1987; 9(2):174-82. PubMed ID: 2952276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.
    McClellan KJ; Plosker GL
    Drugs; 1999 Jul; 58(1):143-57. PubMed ID: 10439934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study.
    Ulvenstam G; Diderholm E; Frithz G; Gudbrandsson T; Hedbäck B; Höglund C; Moelstad P; Perk J; Sverrisson JT
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S67-73. PubMed ID: 1282179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.
    Meeter K; Kelder JC; Tijssen JG; Bucx JJ; Henneman JA; Kerker JP; Hugenholtz PG
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S59-66. PubMed ID: 1282178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris.
    Guermonprez JL; Blin P; Peterlongo F
    Eur Heart J; 1993 Jul; 14 Suppl B():30-4. PubMed ID: 8370370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicorandil for angina.
    Drug Ther Bull; 1995 Dec; 33(12):89-92. PubMed ID: 8777891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
    Gunasekara NS; Noble S
    Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.
    Why HJ; Richardson PJ
    Eur Heart J; 1993 Jul; 14 Suppl B():25-9. PubMed ID: 8370369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicorandil: animal pharmacology.
    Sakai K
    Am J Cardiol; 1989 Jun; 63(21):2J-10J. PubMed ID: 2525321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium channel activators in vasospastic angina.
    Lablanche JM; Bauters C; McFadden EP; Quandalle P; Bertrand ME
    Eur Heart J; 1993 Jul; 14 Suppl B():22-4. PubMed ID: 8370368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.
    Knight C; Purcell H; Fox K
    Cardiovasc Drugs Ther; 1995 Mar; 9 Suppl 2():229-36. PubMed ID: 7647027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure.
    Thadani U
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):735-42. PubMed ID: 9110117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.